AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer's Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2023)

AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer's disease

Related Keywords

United States ,South Korea ,Stefan Klotter ,Aribio Co Ltd ,Aribio United States Branch ,David Greeley ,Chief Medical Officer ,Multi Center Trial ,Early Alzheimer ,Bio United States Branch ,Diese Aktien ,Profi Stefan Klotter ,Aribio ,Present ,Biomarker ,Data ,Hr1001 ,Rom ,Ild ,Moderate ,Lzheimer ,Disease ,Hase ,Study ,Nternational ,Conference ,Parkinson ,Diseases ,Elated ,Neurological ,Disorders ,023 ,